Tong Xu, Chen Rui, Zhang Tong-Tian, Han Yan, Tang Wen-Jian, Liu Xin-Hua
School of Pharmacy, Anhui Medical University, Hefei 230032, PR China.
School of Pharmacy, Anhui Medical University, Hefei 230032, PR China.
Bioorg Med Chem. 2015 Feb 1;23(3):515-25. doi: 10.1016/j.bmc.2014.12.010. Epub 2014 Dec 13.
Thirty seven novel 2-pyrazoline-1-ethanone derivatives were designed, synthesized and evaluated as selective hMAO inhibitors. Among them, compounds 7h (IC50=2.40 μM) and 12c (IC50=2.00 μM) exhibited best inhibitory activity and selectivity against hMAO-A, surpassing that of the positive control Clorgyline (IC50=2.76 μM). Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3)>piperidinyl (4)>morpholinyl (5)>imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity. Molecular docking showed that compounds 7h and 12c were nicely bound to hMAO-A via two hydrogen bonds (SER209, GLU216), one Pi-Pi interaction and three hydrogen bonds (SER209, GLU216, TYR69), one Sigma-Pi interaction, respectively. In addition, the substituent at C3 position of 2-pyrazoline with the N1 acetyl has little effect on MAO-A inhibitory activity. These data support further studies to assess rational design of more efficiently selective hMAO inhibitors in the future.
设计、合成并评估了37种新型2-吡唑啉-1-乙酮衍生物作为选择性人单胺氧化酶(hMAO)抑制剂。其中,化合物7h(IC50 = 2.40 μM)和12c(IC50 = 2.00 μM)对hMAO-A表现出最佳的抑制活性和选择性,超过了阳性对照氯吉兰(IC50 = 2.76 μM)。基于hMAO-A的选择性活性,构效关系(SAR)分析表明,N1取代基贡献的顺序为溴(3)>哌啶基(4)>吗啉基(5)>咪唑基(6),并且在2-吡唑啉核的C3或C5苯环上带有吸电子取代基(-F、-Cl)的化合物具有更强的MAO-A抑制活性。分子对接表明,化合物7h和12c分别通过两个氢键(SER209、GLU216)、一个π-π相互作用和三个氢键(SER209、GLU216、TYR69)、一个σ-π相互作用与hMAO-A紧密结合。此外,2-吡唑啉C3位带有N1乙酰基的取代基对MAO-A抑制活性影响不大。这些数据支持未来进一步开展研究,以评估更高效选择性hMAO抑制剂的合理设计。